ホーム   ->   事業紹介   ->   創薬サービス   ->   バイオロジー   ->   感染症

感染症

クライアントの承認:

  • 証明書つきトラッキング記録

    • 2つのPCCノミネーション(2FIH)につながる13種(統合)の医薬品化学プログラム
    • 20以上の製薬会社、バイオテクノロジー企業、NPOに対するFTEおよびFFSプロジェクト
    • 特定のニーズに応えたクライアント専用に構成したプロジェクトの顕著な増加
    • クライアントの共同出資能力の構築の顕著な増加
    • 新しい能力の拡大
  • 高い顧客満足度

    • 卓越した科学的専門性とサービスに対してクライアントより複数の賞を受賞
    • リピート客と協力関係の拡大
  • フレキシブルなコラボレーションのモデル

先行投資:

  • S熟達した管理部門を経験豊富な研究チーム

    • 米国およびカナダにおけるIDプログラム管理の経験を持つ上級管理部門
    • 産業における研究開発の経験を持つ上級管理部門
    • グループ・リーダーとして経験を持つスタッフ
    • すべての社内研究者(約80名。Ph.D.:7.5%、M.S.:60%、B.S.:30%)に対する社内研修プログラム
    • 高い安定性と機能を持つチーム(ターンオーバー5%超)
  • 広範囲にわたる能力

    • 広範囲の病原体:ウイルス、細菌、菌類
    • In vitro 生物学:化合物スクリーニング、細胞ベース・アッセイ、分子生物学および遺伝学、生化学、酵素学、耐性研究、ゲノミクスほか
    • 抗ウイルス/抗菌薬理、動物モデルによるin vivo有効性試験
  • すぐれたインフラと機材設備

    • BSL-2施設(職員3,000名以上)、抗ウイルスおよび抗菌
    • ABSL-2施設(職員約3,000名、動物室6室、げっ歯類5,000匹の収容能力、ALAAAC認証)、抗ウイルスおよび抗菌
    • 最高水準の機材設備(COBASシステム、POD810ほか)

Key Anti-Viral Services Capabilities

  • HCV:

    • Replicon and viral enzyme assays for SAR support
    • Resistance selection and mutant replicon development
    • Construction of inter-genotypic chimeras
    • Mutant and chimeric replicon fitness and drug-sensitivity analyses
    • Drug combination analysis
    • qRT-PCR analysis of viral load reduction and mutant analysis in 3-week treatment
    • Crystallography of viral proteins and complex
    • Clinical support
      - VLD using COBAS? AmpliPrep and TaqMan 48 systems
      - Clinical mutant phenotyping
    • Genotyping by NGS (in development)
  • HBV:

    HBV hydrodynamic injection mouse model:

    Humanized FRG mouse model for HBV infection

    • Drug screening using HBV producing cell lines and biochemical assay
      (qPCR, Southern blot, Dot blot, ELISA, Capsid assembly assay in vitro)
    • Mutant construction and compound profiling
      - Construction of drug-resistant mutants
      - Compound profiling against LAM-, ETV-, or LDT-resistant mutants by transfection (qPCR)

       

    • Drug combination assay
    • Clinical antiviral response analysis using the COBAS? system
    • Drug-resistant mutant cell lines
    • Mouse hydrodynamic injection model
    • Humanized FRG mouse model for HBV infection
  • RSV:

    • Viral infection assays (CPE, plaque-reduction, Elisa, TaqMan)
    • Viral infection assays (CPE, plaque-reduction, Elisa, TaqMan)MOA studies (time of addition, cell fusion assay,syncytium formation assay, resistance selection…)
    • Mouse nasal infection model
    • Reverse genetics system and autonomous replication system (in development)
    • Cotton rat model (in development)

    RSV MOA studies:

  • Herpes antiviral service platform:

    • HSV (type 1 & 2), HCMV CPE-based screening assay
    • HSV, CMV reporter assay
    • HSV latency mouse model (Ganglion Explant Model)
    • Murine CMV acute & latent infection mouse model (in development)

    HSV latency mouse model

  •  
  • Influenza Virus:

    • Viral infection assays (CPE, plaque, TaqMan) for SAR support
    • CPE-based HTS (384w, Z-factor >0.8), Hit discovery and HTL
    • Hemolysis assay
    • Trypsin susceptibility assay
    • Mini influenza strain panel for anti-viral spectra analysis
    • Drug-resistant selection and seq analysis by NGS; MOA
    • Viral protein or replication complex purification from infected hen eggs
    • Mouse infection model for mortality and/or virus replication

    Validation of H1N1 (WSN) mouse model with Oseltamivir phosphate

  • Multi-virus Antiviral Panel

    • Picornaviridae, Herpesviridae, Orthomyxoviridae, Arteriviridae,Poxviridae, Flaviviridae, Retroviridae, Paramyxoviridae
    • CPE or reporter based assay (96w & 384w, Z-factor>0.6)
  • HIV:

    • Biochemical assays (IN and RT)
    • Pseudo type virus assay
    • HIV infectivity assay(in BSL-3 lab by subcontractor)
  • EV-71 (hand-foot-mouth disease):

    • 3C protease assay
    • Virus CPE and TaqMan assays
    • Mouse model (in development)
  • Dengue antiviral service platform(in development)

    • Dengue screening system: replicon with a reporter
    • Dengue enzyme assays
    • Mutagenesis cassette system

Key Anti-bacterial Capabilities

transferable to different bacterial pathogens

  • Microbiology

    • MIC as per CLSI (serum/protein shift), throughput = ~400 compound x strain / week,can increase with automation, HTS capability available
    • MBC, standard and simplified (coupled with MIC)
    • Spectrum (~10, Gram + & -, as per client request)
    • Time-kill curve
    • Post antibiotic effect (PAE)
    • Synergy/potentiation assay
  • Genetics & Genomics

    • Frequency of resistance (FOR)
    • Drug-induced resistant mutation, isolation & characterization
    • Genomic sequencing by NGS
  • Biochemistry

    • Quantitative MOA
    • Enzymatic assays
    • Macromolecular labeling
    • turnaround time = 1 week
    • throughput per week = ~20compounds, panel of ~15 strains
  • Pharmacology

    • Animal models of bacterial infection
    • In vivo efficacy
    • Deep-thigh model of S. aureus:
      • immuno-compromised host
      • in vivo efficacy of small molecules
      • turnaround time, ~1 week
      Systemic model of S. aureus:
      • immuno-competent or -compromised host
      • in vivo efficacy of small molecules & biologics
      • turnaround time, 1 – 2 week(s)
      Pulmonary model of P. aeruginosa:
      • immuno-competent or -compromised host
      • in vivo efficacy of small molecules
      • turnaround time, 1 week (acute infection)

Key High Throughput Screening Capabilities:

  • Assay development (GPCR, kinases, ion channel, etc...)

  • 753 plates of 384-w Echo-ready plates of diverse and unique WuXi compound collection screening

  • Client compound library screening (up to 1M) in 384-w format

  • 95 GPCR stable cell lines ready in FLIPR assay